Phanes Therapeutics announced positive Phase 2 results for spevatamig (PT886), an anti‑CLDN18.2/CD47 bispecific antibody, presented at ASCO GI 2026. Data showed activity in combination with chemotherapy as first-line treatment for CLDN18.2‑positive metastatic pancreatic ductal adenocarcinoma, with the company highlighting responses and tolerability in the trial population. Phanes positioned the readout as a basis for advancing spevatamig into pivotal development.